https://lifescivc.com/2016/02/quantifying-the-carnage-biotech-markets-in-turmoil/
............
- The vast majority are now below their offer prices. Of the 142 IPOs since January 2013, 74% of them are below their IPO prices. The median stock is down 35% since its IPO; the median return of the NASDAQ Biotech Index (from each company’s offer date) is down only 3%.